English News

  • youtube
  • facebook
  • twitter

Cipla Gets DCGI Nod To Import US’s Moderna mRNA Vaccine In India

In a major development, pharma major Cipla has been cleared from DCGI to import Moderna's Covid vaccine for restricted emergency use in India. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V. Moderna's Covid vaccine is an mRNA-based vaccine with an efficacy rate of 94.1 percent, according to a WHO estimate. Keep watching to know more!